Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to 11.33%.

  • Myriad Genetics' EBITDA Margin fell 19500.0% to 11.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 50.95%, marking a year-over-year decrease of 368900.0%. This contributed to the annual value of 14.74% for FY2024, which is 194300.0% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' EBITDA Margin is 11.33%, which was down 19500.0% from 154.48% recorded in Q2 2025.
  • Myriad Genetics' EBITDA Margin's 5-year high stood at 9.38% during Q3 2024, with a 5-year trough of 154.48% in Q2 2025.
  • For the 5-year period, Myriad Genetics' EBITDA Margin averaged around 30.2%, with its median value being 18.52% (2024).
  • As far as peak fluctuations go, Myriad Genetics' EBITDA Margin skyrocketed by 623000bps in 2021, and later crashed by -1372200bps in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' EBITDA Margin stood at 26.8% in 2021, then decreased by -10bps to 29.36% in 2022, then soared by 46bps to 15.97% in 2023, then decreased by -16bps to 18.52% in 2024, then surged by 39bps to 11.33% in 2025.
  • Its last three reported values are 11.33% in Q3 2025, 154.48% for Q2 2025, and 14.8% during Q1 2025.